Nebido is a long
lasting testosterone injection that is effective for treating patients with
Kallmann syndrome and CHH.
It was first developed and produced by the Bayer health
group and is licenced and distributed under the trade name Reandron 1000 in
Australia, Reandron in Spain and Nebid in Italy.
It is a 4ml injection of testosterone undecanoate that is
given as a deep muscular injection.
Two loading injections are first taken 6 weeks apart then
injections are normally given at 10 to 13 week intervals depending on the
response. Some patients enjoy the convenience of only having to have an
injection every 3 months; it is not unknown for some patients to go 6 months in-between
injections and still achieve normal testosterone levels.
Most patients achieve steady normal physiological levels of
testosterone while using Nebido, without the peaks and troughs seen with
shorter lasting injections.
It is a large volume to inject and sometimes there can be
some short lasting localised pain at the injection site but this can be avoided
by warming the vial in hot water for 5 minutes before injecting to allow the
solution to become more viscous.
The injection is widely available throughout the world apart
from the USA where under the trade name Aveed but it has yet to be licenced.
